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ABSTRACT 
Aims: To evaluate endothelial lipase (EL) protein expression in advanced human carotid artery plaques (HCAP) 
with regard to plaque (in)stability and the incidence of symptoms.  
Methods: HCAP were collected from 66 patients undergoing carotid endarterectomy (CEA). The degree of 
plaque (in)stability was estimated by ultrasound and histology. In HCAP sections, EL-expression was determined 
by immunostaining and the intensity was assessed on a semi-quantitative scale (low: <25%, high: >25% positive 
cells). Monocytes and macrophages in adjacent HCAP sections were stained with a CD163 specific antibody.  
Results: High EL staining was more prevalent in histologically unstable plaques (in 33.3% of fibrous plaques, 
50% of ulcerated non-complicated plaques and 79.2% of ulcerated complicated plaques; χ
2 
test, p=0.004) and in 
the symptomatic group (70.8% vs. 42.9% in the asymptomatic group; χ
2 
test, p=0.028). The majority of EL 
immunostainig was found in those HCAP regions exhibiting a strong CD163 immunostaining. 
Conclusion: EL in HCAP might be a marker and/or promoter of plaque instability and HCAP-related 
symptomatology. 
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Introduction 
Atherosclerosis is a chronic fibro-proliferative and immuno-inflammatory disease affecting large and medium 
size arteries. It is characterized by endothelial dysfunction, local oxidation of circulating lipoproteins (particularly 
low density lipoprotein (LDL)), their accumulation in the vascular wall [1,2] and the activation of 
proinflammatory cytokines [3,4]. Inflammation
 
plays a crucial role in plaque destabilization, as it converts stable 
atherosclerotic plaques, characterized by a fibrous cap covering the necrotic core, into unstable ones, 
characterized by a thinned fibrous cap, intra-plaque hemorrhage, surface ulceration, rupture and thrombosis [5].  
Endothelial lipase (EL) is a member of the triglyceride lipase gene family, expressed by vascular endothelial cells 
(ECs), smooth muscle cells (SMCs) and macrophages [6,7]. It primarily exhibits phospholipase-A1 activity, with 
high affinity for high density lipoprotein (HDL)–phosphatidylcholine (HDL-PC), resulting in the generation of 
bioactive molecules such as lysophosphatidylcholines (lyso-PC) and free fatty acids (FFA) [8]. Acting on HDL, 
EL not only promotes HDL remodeling but also lowering of HDL plasma levels, an independent risk factor for 
atherosclerosis [9]. EL plasma concentrations are strongly associated with elevated plasma interleukin-6 (IL-6), 
tumor necrosis factor (TNF)-α and C-reactive protein (CRP) levels; a profile typical of metabolic syndrome 
[10,11]. EL was also shown to promote the expression of inflammatory cytokines, exemplified by attenuation of 
inflammatory cytokine expression in EL-deficient macrophages [12] as well as by increased production of IL-8 in 
human endothelial cells over-expressing EL [13].  
Taking into account the role of inflammation in plaque destabilization, together with the reported up-regulation of 
EL under inflammatory conditions, we assumed a positive relationship between the expression level of EL and 
the degree of plaque instability. 
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Patients and methods 
 
Patients  
 
Patients were recruited from the Department of Vascular Surgery Sisters of Mercy University Hospital, Zagreb, 
Croatia, between November 1, 2007 and March 1, 2009. Written informed consent from each patient was 
obtained prior to the enrollment in the study, which was performed according to Good Clinical Practice and 
Helsinki Declaration principles. The study was approved by the local Ethics Committee, in accordance with 
institutional guidelines of the Sisters of Mercy University Hospital, Zagreb. 
 
Inclusion and exclusion criteria 
 
Overall 88 patients with significant (70-99%) carotid artery stenosis (confirmed by carotid Color Doppler Flow 
Imaging (CDFI) done by an experienced physician in the University Hospital) were screened for inclusion and 
exclusion criteria. In cases where CDFI imaging was limited by features such as calcified carotid lesions, tortuous 
or kinked carotid arteries or patient body constitution, contrast enhanced magnetic resonance angiography 
(CEMRA) or computed tomography angiography (CTA) were performed. The clinical indication for carotid 
endarterectomy (CEA) was met after examination by the neurologist and vascular surgeon, based on clinical 
presentation and CDFI (or CEMRA/CTA) results, following guidelines for treatment of extra-cranial carotid 
artery disease [14,15]. Exclusion criteria were met in case of acute or chronic infection or inflammatory 
conditions (other than atherosclerosis), severe renal failure (serum creatinine ≥ 200 mmol/L), severe hepatic 
cirrhosis (Child-Pugh Class B or C), neoplasms, recent trauma or surgery, history of ipsilateral CEA or 
radiotherapy and anticoagulant therapy. Patients with a possible cardiac source of embolism detected through the 
patients´ history, electrocardiogram or echocardiography (left ventricular aneurysm, previous large anterior 
cardiac infarction, dilatative cardiomyopathy, aneurysm of inter-atrial septum with patent foramen ovale) were 
excluded from the study.  
 
Definition of symptomatic carotid disease 
 
 The carotid stenosis was considered symptomatic, if a patient had suffered from a focal neurological symptom 
(ipsilateral stroke, transient ischemic attack or monocular blindness), sudden in onset and referable to the 
respective carotid artery within 4 months of CEA.  
 
Patient characteristics, history and medication 
 
Medical history was recorded from all patients, and the presence of vascular risk factors, features of metabolic 
syndrome, previous antihypertensive-, statin- and antiplatelet- treatments were noted. Clinical history was 
assessed for diabetes mellitus, smoking, hypertension, hyperlipidemia, prior acute myocardial infarction, 
symptoms of peripheral vascular disease and family history of CHD or IVC in first-degree relatives under the age 
of 55. The body mass index (BMI) was calculated according to Quetelet’s formula as the ratio of body weight to 
body height squared (kg/m
2
). The waist circumference was measured with a flexible tape, placed on a horizontal 
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plane at the level of the iliac crest. The metabolic syndrome was defined according to the criteria of the 
International Diabetes Federation issued in 2005 (http://www.idf.org/): increased waist circumference (for 
Caucasian European men ≥ 94 cm, for women ≥80 cm) plus any two of the following: triglycerides > 1.7 mmol/L 
(or treatment for elevated triglycerides), HDL cholesterol < 1.03 mmol/l in men or < 1.29 mmol/L in women (or 
treatment for low HDL), systolic blood pressure > 130 mmHg, diastolic blood pressure > 85 mmHg (or treatment 
for hypertension), and fasting plasma glucose > 5.6 mmol/L (or previously diagnosed type 2 diabetes mellitus) . 
Blood pressure was measured with mercurial sphygmomanometer (Riester, Jungingen, Germany) and calculated 
as the average of three measurements taken under standardized conditions in a supine position. Hypertension was 
diagnosed according to World Health Organization (WHO) criteria (blood pressure ≥ 140/90 mmHg or current 
anti-hypertensive treatment). Diabetes was diagnosed in patients with dietary treatment, anti-diabetics or current 
fasting plasma glucose levels higher than 7.0 mmol/L. Hyperlipoproteinaemia was defined if the low-density 
lipoprotein (LDL) cholesterol level was > 3.5 mmol/L, or if a patient was taking a lipid-lowering drug. According 
to cigarette smoking, patients were classified as current smokers (smoking more than five cigarettes within the 
past 3 months), former smokers (> 3 months and < 10 years) or non-smokers. 
 
Methods 
 
Color Doppler Flow Imaging (CDFI) 
 
CDFI of both carotid arteries was performed in all subjects on admission using commercially available equipment 
(Aloka 5500 and Alfa 10 Premium with 10–MHz linear array transducer). The grade of plaque stenosis was 
assessed according to defined criteria [16]. Plaques were divided depending on the presence of the echolucency 
and calcification into: i) fibrous plaques (without echolucent material and calcification), ii) soft plaques 
(predominantly echolucent material), iii) calcified plaques, iiii) mixed plaques (both calcification and echolucent 
material present), and iiiii) non-defined plaques (fibrous plaques with small degree of echolucency and 
calcification). In this regard, echolucency is considered an important factor associated with symptomatic carotid 
disease [17] and plaque vulnerability.  
 
Tissue sampling, preservation of carotid plaque specimens and histology 
 
Carotid specimens were excised by the vascular surgeon (complete tubular specimen without damage to the 
luminal surface) and collected during surgery. They were immediately rinsed in 0.9% saline, fixed for 24 hours in 
5 mL buffered formalin, followed by several phosphate buffered saline (PBS) washes and storage in PBS for 2 
weeks before embedding in paraffin. Plaque morphology was assessed by standard histological examination of 
hematoxylin and eosin-stained (HE) sections (5 µm) and screened for features indicative of plaque vulnerability. 
Taking into account the lack of new, prospectively validated criteria for plaque vulnerability, the Stary 
classification [5] was applied and plaques were defined as: i) fibrous (F) (covered by a smooth luminal surface 
indicative of an intact fibrous cap), ii) ulcerated non-complicated (UNC) (thin fissured or ruptured cap), and iii) 
ulcerated complicated (UC) (thin fissured or ruptured cap with intra plaque hemorrhage and/or thrombus).  
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Immunohistochemistry 
Formalin fixed and paraffin embedded human carotid sections (5µm) were mounted on Superfrost Plus slides 
(Menzel, Braunschweig, Germany) and dried at 40°C over night. Slides were dewaxed twice in xylene for 10 
minutes and rehydrated through a graded series of alcohol. Antigen retrieval was performed by sequentially 
incubating the slides in antigen retrieval buffer pH 9 (Eubio, Vienna Austria) for 2 minutes at 720 Watt and 3 x 5 
minutes at 160 Watt in the microwave. Immunohistochemistry was performed using the Ultravision LP detection 
system (Thermo Scientific, Fremont, USA) according to the manufacturer’s instructions. In brief, endogenous 
peroxidase was blocked by incubation with Hydrogen Peroxide Block (Thermo Scientific) for 10 minutes. 
Thereafter, slides were washed with PBS and unspecific background was blocked with Ultra V Block (Thermo 
scientific) for 8 minutes. Rabbit clonal anti-human CD163 (DB Biotech, clone K20-T, diluted 1:100) and rabbit 
anti-EL serum (1:1500) [18] were diluted in antibody diluent (DAKO) and incubated on slides for 1 h at RT. 
After PBS washing steps, detection was achieved by incubation with the UltraVision HRP-labelled polymer 
system for 15 minutes and 3-amino-9-ethylcarbacole (AEC, Dako, Denmark), according to the manufacturer’s 
instructions. For negative controls, slides were incubated with rabbit IgG Ab-1 (2 µg/ml, Neomarkers) instead of 
the primary antibodies. Nuclei were stained with hemalaun and slides were mounted with Kaiser’s glycerol 
gelatine. Images of sections were taken with an Axiophot microscope equipped with an AxioCam HRc digital 
camera (Zeiss, Oberkochen, Germany). Importantly, all samples were processed simultaneously using the same 
batch of reagents. The expression of EL was evaluated on a semi-quantitative scale by 3 independent, 
experienced investigators blinded to the clinical and histology data. The scoring was arbitrary, as follows: i) (A) 
low staining (less than 25% positive cells), and ii) (B) high staining (more than 25% positive cells).  
Assays 
 
Blood samples for laboratory assays were obtained before surgery at approximately 8 am, following overnight 
fasting. Blood sampled in ethylenediaminetetraacetic (EDTA)-K3 containing tubes was used for hematological 
assays (Coulter-Counter S plus junior, Coulter Electornics Limited, Luton, UK). Coagulation parameters were 
assessed from blood samples in 3.8% sodium citrate. After separation of plasma by centrifugation (3000 g for 10 
min), the Quicktest was performed on a Behring coagulation timer (Dade Behring, Marburg, Germany). Serum 
creatinine, bilirubin, aspartat transaminase, alanin transaminase, blood glucose level, total plasma cholesterol, 
triglyceride, LDL and HDL were measured on automated, multi-channel selective analyzers Olympus AU2700 
and Olympus Fractoscan junior (Olympus Diagnostica GmbH, Hamburg, Germany). High sensitivity (hs) CRP 
concentrations were measured on automated, multichannel selective analyzer Modular (Roche Diagnostics, 
Mannheim, Germany). IL-6 concentrations were measured using a specific chemiluminescent ELISA 
(QuantiGlo; R&D Systems, Wiesbaden-Nordenstadt, Germany) according to the manufacturers’ instructions.  
 
 
Statistical analysis 
 
Data were summarized using mean and standard deviation or median, minimum, maximum as appropriate for 
continuous variables and counts as well as percentages for categorical variables. Data distribution was analyzed 
by Kolmogorov-Smirnov test. According to these results, appropriate parametric or non-parametric tests were 
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used in further analyses. Unpaired Student´s t-test or Mann-Whitney U test was performed to assess differences 
among quantitative variables between symptomatology and immunohistochemistry groups. Differences between 
ordinally scaled histological groups were analyzed with Kruskal-Wallis test, whereas Chi square test was applied 
to analyze differences in qualitative and categorical variables. The association between quantitative data was 
evaluated using Spearman-rank correlation analysis. Data were analyzed using PASW 17.02 (IBM, Chicago, IL, 
USA) software and all p values below 0.05 were considered significant. 
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Results 
Sample size and clinical characteristics 
Out of 88 patients assessed for eligibility, 22 patients were excluded (see Fig. 1). The final study population 
included 66 patients (43 males and 23 females, mean age 67.5) stratified into two groups: the asymptomatic 
group (42 pts) and the symptomatic group (24 pts). The patients´ clinical characteristics and medications are 
shown in Table 1. The two groups did not differ significantly according to age, gender, individual risk factors, 
medication, or coexistence of other vascular diseases (peripheral vascular disease, past myocardial infarction, 
angina pectoris). In the symptomatic group, however, a higher incidence of patients with increased waist 
circumference was found (62.5% vs. 38%; χ
2
test, p= 0.049). The BMI was also higher in the symptomatic group 
(28.2 ± 3.0 vs. 26.8 ± 3.0) but the difference did not reach statistical significance (p= 0.085). Overall, there was 
no significant difference in the number of metabolic risk factors. Basic biochemical and hematological 
parameters as well as inflammatory parameters (WBC, hs-CRP, erythrocyte sedimentation rate, fibrinogen and 
IL-6) did not differ between the groups (Table 2).   
Ultrasound and histological characteristics of plaques 
The grade of carotid artery stenosis detected by CDFI (or CEMRA/CTA) was considerably higher in the 
symptomatic group (χ
2 
test, p=0.027) (Table 3). Additionally, plaques with morphologic characteristics 
suggestive of plaque vulnerability (echolucent zones with or without ulcerated morphology) seen on CDFI were 
more frequent in the symptomatic group (χ
2
 test, p=0.039). Finally, the majority of asymptomatic plaques (50%) 
were F plaques, whereas the majority of symptomatic plaques (50 %) were UC plaques (not statistically 
significant) (Table 3). 
 
EL immunostaining in plaques  
In F plaques (Fig. 2 a-c), the necrotic core was covered with a fibrotic cap with preserved endothelium and only 
few inflammatory cells (Fig. 2 a). In UC plaques (Fig. 2 d-e), in contrast, the necrotic core was covered with 
inflammatory infiltrates, composed of lymphocytes, macrophages, siderophages and importantly of erythrocytes, 
indicating intra-plaque hemorrhage (Fig 2d). In F plaques, a weak EL immunostaining (type A) was detected in 
the endothelial layer and in the fibrous cap (Fig. 2b). The fibrous cap also exhibited moderate CD163 
immunostaining, indicative of the presence of monocytes and macrophages (Fig. 2c). Compared with F plaques, 
EL staining was more pronounced (type B) in UC plaques (Fig. 2e). Here, EL staining localized primarily to cells 
of the inflammatory infiltrate (Fig. 2e), which showed a strong staining for CD163 as well (Fig. 2f).  
Importantly, high intensity EL immunostaining (type B) was most frequently observed in UC plaques (79%; 19 
of 24 pts), followed by UNC and F with 50% (6 of 12 pts) and 33% (10 of 30 pts), respectively (Fig. 3) (χ
2 
test, 
p=0.004). Furthermore, EL immunostaining type B was significantly more prevalent in plaques of symptomatic 
patients (Table 3) (χ
2 
test, p=0.028). Inflammatory markers (IL-6 and hsCRP) as well as HDL plasma levels were 
9 
 
comparable between patients with EL immunostaining type A and B (Mann-Whitney U test, p=0.17 for IL-6; 
p=0.44 for hsCRP; p=0.76 for HDL). 
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Discussion 
The major findings of the present study are: i) higher EL immunostaining in unstable HCAP and ii) higher EL 
immunostaining  in plaques of patients exhibiting HCAP - related symptomatology. Probably the main connector 
between plaque stability, inflammation and EL are macrophages, which play an important role in plaque 
destabilization [19]. Using imunohistochemistry, Azumi et al. [20] identified macrophages and smooth muscle 
cells as main source of EL in HCAP. This was confirmed by a Danish study [21], which detected EL mRNA and 
protein in areas between the fibrotic cap and the necrotic core, co-localizing primarily with macrophage specific 
CD68; however, that study exclusively included symptomatic carotid patients (26 pts). In the present study, the 
intensity of both EL and CD163 immunostaining increased with plaque instability, however not all CD163 
positive regions/cells were positive for EL staining. This might be explained by the fact that CD163 (a scavenger 
receptor for haptoglobin/hemoglobin complexes) is expressed by both monocytes and macrophages [22], whereas 
EL protein expression is negligible in monocytes but prominent in macrophages and foam cells [21]. 
Accordingly, the up-regulation of EL (in plaque macrophages) might aggravate inflammation by promoting 
cytokine production [13,12] or LDL uptake [23,24].   
Most studies, addressing EL in the context of inflammation and atherosclerosis, were based on the plasma levels 
of EL. In healthy subjects with a family history of premature coronary heart disease (CHD), increased plasma EL 
concentrations were associated with subclinical CHD [10]. Badelino and al. [25] reported increased plasma EL 
levels under experimental endotoxemia and in patients with metabolic syndrome, a known proinflammatory 
condition.  
In the present study, where all patients exhibited advanced atherosclerotic lesions in at least one (target) artery, 
inflammatory serum markers, such as IL-6 and hsCRP, were not different between patients with low and high EL 
expression in HCAP (Mann-Whitney U test, p=0.17 for IL-6; p=0.44 for hsCRP). This might probably reflect the 
diffuse nature of atherosclerosis that masks the effect of increased local inflammatory molecule production in 
unstable HCAP, highlighting the importance and relevance of localized EL expression at the site of pathology. 
Furthermore, this lack of association between local EL expression in HCAP and IL-6 and hsCRP might be due to 
the analysis of the total cohort irrespective of gender [26], age [27], or routine exercise [28] - factors with 
established impact on the plasma levels of inflammatory molecules. Additionally, the expression of inflammatory 
molecules might have been differently affected by medication - considering pharmacological properties, dosage 
and interactions of the therapeutics, and the duration of the treatment.   
In the present study, there was no significant difference in plasma HDL levels between patients with high (B) and 
low (A) EL expression in plaques (mean value in both groups 1.3 mmol/L, Mann-Whitney U test, p=0.76). 
Importantly, in the study group, 69% of patients were treated with statins (atorvastatin 19 pts, simvastatin 23 pts, 
fluvastatin 3 pts) known to increase HDL plasma levels by regulating various molecules that participate in 
reverse cholesterol transport, such as apo AI [29], scavenger receptor B type I (SR-BI) [30], or ATP binding 
cassette A1 (ABCA1) [31]. Furthermore, statins were shown to decrease EL expression [32,33]. Considering this 
and the fact that patients were treated with various doses of different statins, known to vary in their potency to 
modulate HDL plasma levels, it is tempting to assume that the lack of association between EL in HCAP and HDL 
plasma levels in the present study is partially due to medication. In addition to statins, angiotensinogen II (AT II) 
receptor antagonists (10 pts), as well as angiotensin converting enzyme inhibitors (33 pts) might, considering the 
capacity of AT II to modulate EL expression [34], affect the relationship between EL in HCAP and HDL plasma 
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levels as well as between EL in HCAP and inflammatory markers. Interestingly, neither statins nor ACE 
inhibitors impacted significantly the intensity of EL immunostaining in HCAP (not shown). Furthermore, 
increased EL mass in HCAP does not necessarily have to be accompanied by increased local EL phospholipase 
activity, considering reduced phospholipase activity of various genetic variants [35]. Finally, the relative 
contribution of EL in HCAP to the total systemic EL phospholipase activity might be too low to significantly 
affect HDL plasma levels. Besides, even serum EL levels were found not to correlate significantly with HDL 
levels [36,11].   
The results of our study are in line with previous reports showing no obligatory association between 
symptomatology of carotid disease and histological features of plaque vulnerability. This might be due to: i) the 
lack of strong uniform criteria for plaque instability, ii) artificial (laboratory) disruption of the plaque surface, or 
iii) the fact that some unstable plaques resolve spontaneously without causing symptoms [37-39]. In addition, 
some of the ischemic events are not caused by the carotid lesion itself, but rather by embolic material derived 
from heart and aorta. Using echocardiography, we could exclude only some of the patients with suspected cardiac 
source of embolism. Moreover, it is known that not only the vulnerable plaque makes the patient vulnerable, but 
also that the vulnerable environment (e.g. blood prone to thrombosis) plays an important role in the overall 
outcome.  
To our knowledge this is the first study addressing the relationship between the intensity of EL immunostaining 
in HCAP and the degree of HCAP vulnerability and HCAP-related symptomatology. The higher EL 
immunostaining in vulnerable and symptomatic HCAP suggests a strong involvement of EL in the local 
inflammatory process, a key element of plaque destabilization. Whether EL in HCAP is only a marker or an 
active causative factor for cerebrovascular events and whether EL in HCAP has a prognostic value for the 
incidence and velocity of carotid artery re-stenosis or other cerebro- and/or cardio-vascular events remains to be 
examined.  
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Figure legends 
 
Figure 1 Flow chart of the study 
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Figure 2 HCAP histology and immunostaining of EL and CD163  
For histology, serial sections of HCAP were stained with HE and for immunohistochemical detection of EL and 
CD163, with antibodies against EL and the mononocyte/macrophage marker CD163. A fibrous plaque (F) is 
shown in panels a-c: (a) HE-stained F plaque with fibrous cap (filled arrow heads) and necrotic core (asterisk). 
(b) EL staining (red) in the endothelium (empty arrows) and in cells within the fibrous cap (filled arrows). (c) 
CD163 immunostaining (red). 
An ulcerated plaque (UC) is shown in panels d-f: (d) HE-stained UC plaque with inflammatory infiltrate 
(asterisks) and intra-plaque erythrocytes (empty arrow heads). (e) EL immunostaining. (f) CD163 staining. Scale 
bar represents 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The intensity of EL immunostaining increases with plaque instability 
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The intensity of EL immunostaining was determined in different types of plaques, defined by histology as fibrous 
plaques (F), ulcerated non-complicated plaques (UNC), and ulcerated complicated plaques (UC). Grey columns 
represent the number of patients exhibiting low intensity of EL immunostaining (A), whereas black columns 
denote those with high intensity of EL immunostaining (B) in plaques. 79.2% of UC plaques were type B, 50% of 
UNC plaques were type B, whereas 66.7% of F plaques exhibited type A immunostaining. χ
2 
test, p=0.004. 
 
 
 
 
 Table 1. Clinical characteristics and patient medications at the enrollment 
into the study 
 
Clinical characteristic and medications asymptomatic 
(n=42) 
symptomatic 
(n=24) 
  
                    (mean±SD) 
Age (years; median, range)  69 (43-83) 65.5 (50-84) 
BMI (kg/m
2
; mean ±SD) 26.8 ± 3.0 28.2 ± 3.0 
Waist circumference (cm; mean±SD ) 91.6 ±7.51 94.1 ± 8.5 
  
                 No. (%) of patients 
Gender:    
   men 28 (66.6) 15 (62.5) 
   women  14 (33.3) 9 (37.5) 
Increased waist circumference† 16 (38.1) 15 (62.5) 
Cardiovascular risk factors:   
   Arterial hypertension 36 (85.7) 22 (91.6) 
   Hyperlipoproteinaemia 31 (73.8) 21 (87.5) 
   Diabetes mellitus or glucose intolerance 20 (47.6) 15 (62.5) 
   Tobacco (current or recent) 16 (38.0) 14 (58.3) 
   Family history‡ 9 (21.4) 4 (16.7) 
Peripheral vascular disease 21 (50.0) 9 (37.5) 
Coronary artery disease  12 (28.5) 6 (25.0) 
Medications:   
   Statins 29 (69.0) 16 (66.6) 
   ACE inhibitors 21 (50.0) 12 (50.0) 
   Angiotensin receptor  blockers  7 (16.6) 3 (12.5) 
   Calcium channel blockers  19 (45.2) 8 (33.3) 
   Acetyl salicylic acid 25 (59.2) 19 (79.1) 
No of metabolic elements present   
   0 3 (7.1) 1 (4.2) 
   1 4 (9.5) 2 (8.3) 
   2 15 (35.7) 5 (20.8) 
   3 8 (19.0) 4, (16.7) 
   4 9 (21.4) 11 (45.8) 
   5 3 (7.1) 1 (4.2) 
Abbreviations: BMI–body mass index, ACE–angiotensin-converting enzyme  
† Fisher exact test,  p=0.049 
‡familiar history of cardiovascular disease or stroke in first relatives younger than 55 years 
 
 Table 2. Patient blood parameters at the enrollment in the study 
 asymptomatic 
(n=42) 
symptomatic 
(n=24) 
Parameter (mean±SD) 
   Platelets (x10
9
/L) 237 ±67 219 ±52 
   Hemoglobin (g/L) 137.8 ±14.1 140.5 ±9.1 
   WBC (x10
9
/L) 8.21 ±2.4 7.33 ±1.65 
   fibrinogen (g/L) 4.28 ±0.86 4.62 ±1.02 
   APTT (sec) 25.2 ±4.6 26.4 ±3.4 
   PT (%) 104.3 ±11.8 103.6 ±8.9 
   ESR (mm/h)  18.5 ±8.7 19.2 ±11.2 
   hs-CRP (µg/mL) 1.4 (0.1-23.0) 
§
 3.6 (0.4-31.5) 
§
 
   serum creatinine (µmol/L) 95.1 ±21.7 96.7 ±20.4 
   Total cholesterol (mmol/L) 5.2 ±1.5 5.5 ±1.4 
   LDL (mmol/L) 3.1 ±1.3 3.5 ±1.3 
   HDL (mmol/L) 1.3 ±0.4 1.3 ±0.3 
   Triglycerides (mmol/L) 1.8 ±0.7 1.8 ±0.9 
   Lp(a) (mg/dl) 23.4 ±21.2 19.9 ±18.7 
   IL-6 (pg/ml) 1.4 (0.0-15.4) 
§
 1.8 (0.0-43.3)
 §
 
Abbreviations: WBC White blood cells; APTT–activated partial thromboplastin time; 
PT–prothrombin time; ESR–erythrocyte sedimentation rate at first hour;  hs-CRP–high 
sensitivity C-reactive protein; LDL–low density lipoprotein; HDL–high density 
lipoprotein; IL-6–interleukin-6; Lp(a)–Lipoprotein (a ); 
§
 results are median (range) 
 
  
Table 3. Ultrasound and histological characteristics of carotid stenosis  
 No. (%) of patients 
(total n=66) 
 asymptomatic 
(n=42) 
symptomatic 
(n=24) 
Grade of stenosis (%) †   
   70-85 18 (42.9) 4 (16.7) 
   85-95 5 (11.9) 1 (4.2) 
   95-99 19 (45.2) 19 (79.2) 
Morphology of plaques by ultrasound ‡   
   fibrous 5 (11.9) 0 (0.0) 
   soft 11 (26.2) 12 (50.0) 
   calcified 4 (9.5) 3 (12.5) 
   mixed 14 (33.3) 9 (37.5) 
   non-defined 8 (19.0) 0 (0.0) 
Histology classification   
   fibrous 21 (50.0) 9 (37.5) 
   UNC 9 (21.4) 3 (12.5) 
   UC 12 (28.6) 12 (50.0) 
Immunohistochemistry for EL §   
  A (0-25% cells) 24 (57.1) 7 (29.2) 
  B (>25% cells)  18 (42.9) 17 (70.8) 
Abbreviations: UNC–ulcerated non complicated plaques (without intra-plaque hemorrhage 
and/or thrombus); UC–ulcerated complicated (with intra-plaque hemorrhage and/or thrombus); 
EL-endothelial lipase. † χ
2
, p = 0.027; ‡ χ
2
, p = 0.039; § χ
2
, p = 0.028 
 
 
 
